Almost every synthetic research peptide begins as a swollen bead of cross-linked polystyrene in a filter vessel. Solid-phase peptide synthesis — SPPS — is the method behind the material, and it explains why two vials carrying the same label can be very different reagents. The chemistry is repetitive: add one protected amino acid, wash, remove a protecting group, wash, repeat. What varies between suppliers is not the route but the discipline with which each cycle is driven to completion and the rigour of the purification that follows.
This is SPPS explained from the manufacturing side: what the Fmoc cycle consists of, what comes off the resin, and why the crude material from a completed synthesis is never the finished reagent. It is background chemistry for laboratories evaluating research material — not preparation or usage guidance of any kind.
The idea: anchor the chain to something you can filter
Building a peptide in solution means isolating and purifying an intermediate after every bond-forming step; losses compound, and beyond a handful of residues it becomes impractical. The insight that changed peptide manufacturing came from R. Bruce Merrifield at the Rockefeller Institute (later Rockefeller University), published in the Journal of the American Chemical Society in 1963 as "Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide". Merrifield anchored the first amino acid covalently to an insoluble resin bead. Because the growing chain is held on a solid that sits on a frit, reagents can be used in large excess to force each reaction toward completion and then washed away; no intermediate is ever isolated. Merrifield received the 1984 Nobel Prize in Chemistry for developing methodology for chemical synthesis on a solid matrix.
The support is typically polystyrene cross-linked with around 1% divinylbenzene, carrying a chemical linker that joins the peptide to the bead. The linker is not incidental: it dictates what the C-terminus becomes on release — a carboxylic acid from a Wang-type linker, an amide from a Rink amide linker. The second consequence is automation: add, mix, drain, wash is a sequence a machine can repeat faithfully hundreds of times, which is what makes routine synthesis of a 15- or 30-residue sequence practical.
The Fmoc cycle
The original Boc chemistry uses repeated acid treatment and a harsh final cleavage; modern Fmoc peptide synthesis — Fmoc/tBu chemistry — is what most commercial production now uses. Its advantage is orthogonality. The 9-fluorenylmethoxycarbonyl (Fmoc) group, introduced to peptide chemistry by Carpino and Han in 1970, protects the N-terminal amine and is base-labile: piperidine removes it. Side chains carry acid-labile tert-butyl-type protection, untouched by base. The temporary N-terminal group can therefore be stripped once per residue without disturbing the permanent side-chain protection, which stays on to the end.
The chain is assembled from the C-terminus toward the N-terminus: the C-terminal residue sits on the resin, and every new residue joins at the free amine at the growing end. One cycle installs one residue.
| Step | Operation | Purpose |
|---|---|---|
| 1 | Deprotect — piperidine in DMF | Removes the N-terminal Fmoc group, exposing a free amine |
| 2 | Wash — DMF | Clears base and the fulvene by-product before coupling |
| 3 | Activate | A coupling reagent (carbodiimide plus additive, or a uronium salt with base) makes the next residue's carboxyl reactive |
| 4 | Couple | Amide bond forms with the resin-bound amine; excess reagent drives it toward completion |
| 5 | Wash | Excess reagents and by-products filtered away — the whole point of the solid support |
| 6 | Cap (optional) | Acetic anhydride acetylates any amine that failed to couple, stopping that chain permanently |
| 7 | Repeat | Once per remaining residue in the sequence |
Completion is monitored rather than assumed. A ninhydrin (Kaiser) colour test on a sample of resin indicates whether free amines remain after a coupling; automated instruments can also track the ultraviolet absorbance of the fulvene–piperidine adduct released at each deprotection, giving a per-cycle record.
Cleavage and global deprotection
When the last residue is in place, a single acidolysis does two jobs at once. A trifluoroacetic acid (TFA) based cocktail — commonly around 95% TFA with water and triisopropylsilane, with thiol scavengers for sensitive sequences — severs the linker to release the peptide and strips the acid-labile side-chain protection.
Those protecting groups leave as reactive carbocations, which is why scavengers are not optional: without them the cations alkylate susceptible side chains such as tryptophan, tyrosine, methionine and cysteine, generating adducts chemically close to the target. The peptide is then precipitated with cold diethyl ether, collected, washed, redissolved in aqueous acetonitrile and freeze-dried to a crude powder.
Why crude peptide is never the final product
That powder is a mixture. Every coupling and every deprotection is a real reaction with an efficiency below 100%, and the shortfalls accumulate along the chain. If an amine fails to couple in one cycle but reacts in the next, the chain that emerges is missing a residue in the middle — a deletion sequence. If a chain stops growing altogether, the product is a truncation. Capping converts the first failure mode into the second, which is preferable only because truncations are easier to separate.
The arithmetic is unforgiving and worth doing. A pentadecapeptide — a 15-residue sequence such as BPC-157 — requires 14 couplings. At an average step efficiency of 99%, the fraction of chains carrying the complete sequence is 0.9914, roughly 87%, before any other side reaction is counted. At 99.5% per step it is around 93%. Extend the same 99% figure to a 30-residue chain and full-length material falls to about 75%. These are illustrative figures, not measurements of any batch, but they show why length drives crude complexity.
Layered on top are side reactions that do not change chain length: incomplete Fmoc removal, epimerisation during activation, aspartimide formation at aspartate-containing motifs, oxidation of methionine, a side-chain protecting group surviving cleavage, alkylation adducts from poor scavenging. These are the hardest to remove precisely because they resemble the target: a single-residue deletion can sit almost on top of the main peak, and an epimer has exactly the same molecular mass as the peptide it contaminates.
Crude peptide from a completed synthesis is a mixture, not a product. The only meaningful evidence that a lot is what the label says is batch-specific analytical data on the finished material — not a description of the synthesis route, and not a purity figure inherited from another batch.
Purification and quality control
The crude powder is redissolved and loaded onto preparative reversed-phase HPLC, typically a C18 stationary phase eluted with a shallow water/acetonitrile gradient containing an acidic ion-pairing modifier such as 0.1% TFA, with ultraviolet detection in the 214–220 nm region where the amide bond absorbs. The main peak is collected in fractions; those fractions are re-analysed individually, and only the ones meeting specification are pooled. Everything else is discarded.
Pooled fractions are then freeze-dried. Because the mobile phase was acidic, the peptide is isolated as a salt — commonly the trifluoroacetate — and retains residual water. This is why the mass in a vial is not entirely peptide, a distinction explained in peptide purity vs net peptide content.
Quality control on the finished lot answers two separate questions. Analytical RP-HPLC gives an area-percent purity for that lot; mass spectrometry confirms the measured molecular mass matches the intended sequence. Neither substitutes for the other, as set out in RP-HPLC vs mass spectrometry. The material is lyophilised into its sealed vial, labelled with a batch number, and tied to a certificate of analysis belonging to that batch and no other.
Why this matters when you buy
A laboratory cannot inspect a synthesis. It can inspect the output of one, and synthesis quality shows up directly in the chromatogram. A single dominant peak on a flat baseline is the readable signature of couplings driven to completion, effective capping, clean cleavage with adequate scavenging and disciplined fraction pooling. A cluster of small peaks crowding the main one is the signature of the opposite.
The due-diligence position follows. Ask any supplier for chromatography tied to the batch on the vial, with the analytical conditions stated and a mass-spectrometry record alongside it — not a generic document reused across lots. NorthScientific does not currently publish independent third-party analysis for the material it holds. Terms of supply are at /terms; the range is in the catalogue.
Materials referenced: BPC-157 · Ipamorelin · CJC-1295 No DAC · full catalogue
Everything NorthScientific supplies is for laboratory research use only. Nothing on this page is dosing, preparation, administration or usage guidance, and nothing we sell is for human or veterinary consumption.